Table 4. Select studies evaluating the... | American Society of Hematology

Table 4.

Select studies evaluating the outcome of relapsed/refractory PMBCL

Study	n (% rituximab primary treatment) Year of primary diagnosis	Outcomes in intention to transplant			Post-ASCT outcomes		% Salvage RT pre- vs post- ASCT
Study	n (% rituximab primary treatment) Year of primary diagnosis	PFS, % (y)	OS, % (y)	ASCT rate, %	PFS/EFS, % (y)	OS, % (y)	% Salvage RT pre- vs post- ASCT
Kuruvilla et al, 2005¹⁰⁴	37 3 1995-2004	15 (2)	15 (2) Rel 29 (2) Ref 31 (2)	22	57 (2)	67 (2)	NR
Aoki et al, 2015⁷⁷	44 66 1996-2012	NR	NR	NR	61 (4)^*	70 (4)^* Rel 73 (4) Ref 65 (4)	NR
Avivi et al, EBMT, 2018⁷⁸ †	86 85 2000-2012	NR	NR	NR	62 (5) Rel 64 (5) Ref 39 (5)	71 (5) 77 (5) 41 (5)	30 pre
Vardhana et al, 2018⁷⁶	60 40 1989-2014	57 (3)	61 (3)	85	60 (3)	65 (3)	90 pre
Hayden et al, 2020¹³	31 100 2001-2018	NR	48 (5)	Rel 78 Ref 75	NR	57 (5) Rel 71 (5) Ref 50 (5)	36 post

Study	n (% rituximab primary treatment) Year of primary diagnosis	Outcomes in intention to transplant			Post-ASCT outcomes		% Salvage RT pre- vs post- ASCT
Study	n (% rituximab primary treatment) Year of primary diagnosis	PFS, % (y)	OS, % (y)	ASCT rate, %	PFS/EFS, % (y)	OS, % (y)	% Salvage RT pre- vs post- ASCT
Kuruvilla et al, 2005¹⁰⁴	37 3 1995-2004	15 (2)	15 (2) Rel 29 (2) Ref 31 (2)	22	57 (2)	67 (2)	NR
Aoki et al, 2015⁷⁷	44 66 1996-2012	NR	NR	NR	61 (4)^*	70 (4)^* Rel 73 (4) Ref 65 (4)	NR
Avivi et al, EBMT, 2018⁷⁸ †	86 85 2000-2012	NR	NR	NR	62 (5) Rel 64 (5) Ref 39 (5)	71 (5) 77 (5) 41 (5)	30 pre
Vardhana et al, 2018⁷⁶	60 40 1989-2014	57 (3)	61 (3)	85	60 (3)	65 (3)	90 pre
Hayden et al, 2020¹³	31 100 2001-2018	NR	48 (5)	Rel 78 Ref 75	NR	57 (5) Rel 71 (5) Ref 50 (5)	36 post

Outcomes are for >1 CR/PR and refractory disease.

NR, not reported; ref, refractory; rel, relapsed.

Five patients underwent allo-SCT.

Includes 16 patients who underwent transplant in first remission (included in overall PFS and OS estimate only).